Oncotarget

Research Papers:

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer

Anjie Zhu, Peng Yuan _, Feng Du, Ruoxi Hong, Xiaoyan Ding, Xiuqing Shi, Ying Fan, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li and Binghe Xu

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:76628-76634. https://doi.org/10.18632/oncotarget.10532

Metrics: PDF 2127 views  |   HTML 2638 views  |   ?  


Abstract

Anjie Zhu1, Peng Yuan1, Feng Du1, Ruoxi Hong2, Xiaoyan Ding3, Xiuqing Shi4, Ying Fan1, Jiayu Wang1, Yang Luo1, Fei Ma1, Pin Zhang1, Qing Li1, Binghe Xu1

1Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC), Beijing, China

2Department of Medical Oncology, Sun Yat-sen University Cancer center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

3Department of Medical Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China

4Department of Medical Oncology, Yuhuangding Hospital, Yantai, Shandong, China

Correspondence to:

Peng Yuan, email: [email protected]

Binghe Xu, email: [email protected]

Keywords: SPARC, osteonectin, triple-negative breast cancer, prognosis

Received: January 12, 2016    Accepted: May 02, 2016    Published: July 11, 2016

ABSTRACT

SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up to 10 years of clinical follow-up data. High SPARC expression (IRS ≥3) was detected in 52.1% of primary tumors. Patients expressing high SPARC levels had worse disease-free survival (DFS) (HR=1.58, 95% CI: 1.01-2.47, P=0.044) and overall survival (OS) (HR=1.74, 95% CI: 1.06-2.85, P=0.029) than patients with lower SPARC levels. Furthermore, high SPARC expression was an independent prognostic factor for both DFS (HR=1.73, 95% CI: 1.10-2.73, P=0.018) and OS (HR=1.90, 95% CI: 1.14-3.16, P=0.014) in TNBC patients. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10532